62nd ASH Annual Meeting and Exposition: 605. Molecular Pharmacology, Drug Resistance

Oral and Poster Abstracts
Poster

Adult, antibodies, Biological, Follicular Lymphoma, Leukemia, Animal models, CLL, Diseases, drug-drug interaction, Lymphoma (any), Marginal Zone Lymphoma, Non-Biological, cell regulation, Combinations, Mantle Cell Lymphoma, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DLBCL, immune cells, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, pharmacology, Quality Improvement , flow cytometry, RNA sequencing, pathogenesis, pathways, signal transduction

2786

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Vivian Changying Jiang, PhD¹, Yang Liu, PhD¹^*, Joseph McIntosh, BS¹^*, Alexa A Jordan, BS¹^*, Angela Leeming¹^*, Zhihong Chen¹^*, Katti A. Jessen, PhD², Brian J. Lannutti, PhD² and Michael Wang, MD^1,3

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²VelosBio Inc., San Diego, CA
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

2787

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Maciej Szydlowski, PhD¹^*, Filip Garbicz, MD^1,2^*, Ewa Jabłońska, PhD¹^*, Patryk Górniak, PhD¹^*, Beata Pyrzynska, PhD³^*, Kamil Bojarczuk, PhD^1,4^*, Dorota Komar, PhD¹^*, Monika Prochorec-Sobieszek, MD, PhD⁵^*, Anna Szumera-Ciećkiewicz, MD, PhD⁵^*, Grzegorz Rymkiewicz, MD, PhD⁶^*, Magdalena Cybulska, DVM⁷^*, Małgorzata Statkiewicz⁷^*, Marta Gajewska, PhD⁷^*, MIchał Mikula, PhD⁷^*, Aniela Golas, PhD⁸^*, Joanna Domagała, MSc³^*, Magdalena Winiarska³^*, Agnieszka Graczyk-Jarzynka³^*, Emilia Bialopiotrowicz, PhD¹^*, Anna Polak, PhD¹^*, Joanna Barankiewicz, MD⁹^*, Bartosz Pula, MD, PhD⁹^*, Michael R Green, PhD^10,11, Dominika Nowis, MD, PhD¹²^*, Jakub Golab³^*, Andrea Massimiliano Tomirotti, PhD¹³^*, Krzysztof Brzózka, PhD¹⁴, Mariana Pacheco-Blanco¹⁵^*, Kristyna Kupcova¹⁵^*, Ondrej Havranek, MD, PhD¹⁵, Bjoern Chapuy, MD, PhD⁴ and Przemyslaw Juszczynski, MD, PhD¹^*

¹Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
²Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland
³Department of Immunology, Medical University of Warsaw, Warsaw, Poland
⁴Department of Hematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany
⁵Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
⁶Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
⁷Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
⁸Ryvu Therapeutics, Cracow, Poland
⁹Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
¹⁰Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
¹²Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, POL
¹³Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia, Italy
¹⁴Ryvu Therapeutics S.A., Cracow, Poland
¹⁵BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic

2788

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel W Robbins¹^*, Aileen Kelly, PhD¹^*, May Tan¹^*, Joel McIntosh¹^*, Jeffrey Wu¹^*, Zef Konst¹^*, Daisuke Kato¹^*, Ge Peng¹^*, Jeff Mihalic¹^*, Dahlia Weiss¹^*, Luz Perez¹^*, Jennifer Tung¹^*, Anna Kolobova¹^*, Sasha Borodovsky, PhD¹^*, Ryan Rountree¹^*, Austin Tenn-McClellan¹^*, Mark Noviski¹^*, Jordan Ye¹^*, Steve Basham¹^*, Timothy Ingallinera¹^*, Jenny McKinnell¹^*, Dane E Karr¹^*, Janine Powers, PhD¹^*, Cristiana Guiducci, PhD²^* and Arthur Sands¹^*

¹Nurix Therapeutics, San Francisco, CA
²Nurix Inc, San Francisco, CA

2789

Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Alexa A Jordan, BS¹^*, Joseph McIntosh, BS¹^*, Yang Liu, PhD¹^*, Angela Leeming¹^*, William Lee¹^*, Ingrid Karlsson, PhD²^*, Linda Mårtensson, PhD²^*, Mathilda Kovacek²^*, Ingrid Teige, PhD²^*, Björn Frendéus, PhD²^*, Michael Wang, MD^1,3 and Changying Changying Jiang, PhD¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²BioInvent International AB, Lund, Sweden
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

2790

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Tommy Li, PhD¹^*, Ida H Hiemstra, PhD²^*, Christopher Chiu, PhD¹^*, Roberto S Oliveri, MD, PhD³^*, Dena DeMarco¹^*, Theodora W. Salcedo, PhD, DABT¹^*, Frederikke Lihme Egerod, PhD⁴^* and Manish Gupta, PhD¹^*

¹Genmab, Princeton, NJ
²Genmab A/S, Utrecht, Netherlands
³Genmab A/S, Copenhagen, Denmark
⁴Genmab, Copenhagen, Denmark

2791

A Targeted Drug Screen Reveals Potent Combinatorial Inhibitors of T-PLL Primary Patient Cells

Sanna Timonen^1,2,3^*, Jana von Jan⁴^*, Aleksandr Ianevski³^*, Anil K Giri³^*, Matti Kankainen, PhD^1,2^*, Marco Herling, MD⁴^*, Tero Aittokallio, PhD³^* and Satu Mustjoki, MD, PhD^1,2

¹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
²Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland
³Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
⁴Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany

2792

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Olga Dashevsky, PhD^1,2^*, Ricardo De Matos Simoes, PhD^1,2^*, Ryosuke Shirasaki, MD^1,2,3^*, Michal Sheffer, PhD^1,2^*, Eugen Dhimolea, PhD^1,2^*, Sara Gandolfi, MD^1,2^*, Huihui Tang, PhD^1,2^*, Sondra L. Downey-Kopyscinski, PhD^1,2^*, Megan Bariteau, B.Sc.⁴^*, Jeffrey Sorrell, BA¹^*, Brian Glassner, PhD^1,2^*, John Doench, PhD⁵^*, Larry H. Boise, PhD⁶, Jonathan D. Licht, MD⁷, Aedin Culhane, PhD⁸^*, William C. Hahn, MD, PhD^1,2^*, Francisca Vazquez, Phd²^*, Aviad Tsherniak, PhD²^* and Constantine S. Mitsiades, MD, PhD^2,9

¹Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Broad Institute of MIT and Harvard, Cambridge, MA
³Dept. of Medical Oncology, Teikyo university hospital, Tokyo, TKY, Japan
⁴Dana Farber Cancer Institute, Boston, MA
⁵Broad Institute, Cambridge, MA
⁶Emory University, Atlanta, GA
⁷Department of Medicine, University of Florida, Gainesville, FL
⁸Dept. of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III